
VitriVax Secures $87 Million Series C Funding to Advance Lyme Disease Vaccine Candidate into Clinical Development and Expand Pipeline
VitriVax Raises $87 Million in Oversubscribed Series C Financing to Advance Lyme Disease Vaccine and Expand ALTA® Technology Pipeline VitriVax, a vaccine development and formulation technology company, has announced the successful close of an oversubscribed $87 million Series C financing…













